IRLAB Therapeutics (OMX: IRLABA)

Currency in SEK

Last close As at 26/05/2023


−0.68 (−7.57%)

Market capitalisation


Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).

PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.

IRLAB Therapeutics_resized



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Viktor Siewertz


Balance Sheet

Forecast net cash (SEKm)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (20.2) (14.0) (78.0)
Relative (18.6) (12.9) (78.7)
52 week high/low SEK41.8/SEK8.3


IRLAB has announced an agreement with the McQuade Center for Strategic Research and Development (MSRD), a member of the Otsuka family of pharmaceutical companies. As part of this agreement, MSRD will evaluate IRLAB’s neuropsychiatric preclinical programmes: IRL757 (apathy) and IRL942 (cognitive function). MSRD searches for, identifies and funds innovative early-stage R&D programmes that it believes have the potential to build the future portfolio of Otsuka products. We view this external interest from MSRD as encouraging for IRLAB’s preclinical portfolio; discussions are expected in coming months regarding a potential R&D collaboration for these programmes.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2021A 207.9 56.1 91.1 176.0 4.7 8.2
2022A 61.3 (108.3) (113.1) (218.0) N/A N/A
2023E 0.2 (205.1) (208.4) (402.0) N/A N/A
2024E 0.2 (187.0) (190.2) (367.0) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free